A Stewardship Approach to Combating Multidrug-Resistant Acinetobacter baumannii Infections With Minocycline
- 1 May 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 20 (3) , 184-187
Abstract
Background Antimicrobial Stewardship Programs should consider old antimicrobials for emerging multidrug-resistant (MDR) organisms such as Acinetobacter baumannii. Our purpose is to evaluate susceptibilities of minocycline to MDR-A. baumannii and assess the outcomes of patients treated with minocycline. Methods Consecutive isolates from 67 patients with MDR-A. baumannii were tested to determine susceptibilities to tetracycline, minocycline, tigecycline, ampicillin/sulbactam, imipenem/cilastatin, and colistin. Patients receiving minocycline from September 1, 2010, to March 31, 2011 were analyzed for demographics, penicillin allergy, clinical and microbiologic response, length of stay (LOS), infection-related LOS, and mortality. Results Minocycline was susceptible to 32 (48%) of 67 A. baumannii isolates. Of the imipenem/cilastatin- and ampicillin/sulbactam-resistant isolates, minocycline was susceptible to 18 (38%) of 47. Five patients received minocycline in combination with ampicillin/sulbactam or colistin for pneumonia (n = 3), bacteremia (n = 1), and skin and soft tissue infection (n = 1). The median treatment duration, LOS, and the infection-related LOS were 10, 34, and 21 days, respectively. All patients had microbiologic cure, and 4 had clinical response. Conclusions Minocycline showed clinical utility for MDR-A. baumannii infections. Antimicrobial Stewardship Programs should consider minocycline for MDR-A. baumannii infections and monitor patient outcomes.Keywords
This publication has 11 references indexed in Scilit:
- Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated PneumoniaJournal of Intensive Care Medicine, 2010
- Treatment ofAcinetobacterInfectionsClinical Infectious Diseases, 2010
- Minocycline—an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumanniiInternational Journal of Antimicrobial Agents, 2009
- In Vitro Activities of Tigecycline, Minocycline, and Colistin-Tigecycline Combination against Multi- and Pandrug-Resistant Clinical Isolates of Acinetobacter baumannii GroupAntimicrobial Agents and Chemotherapy, 2009
- Antimicrobial Resistance:Acinetobacter baumannii:Epidemiology, Antimicrobial Resistance, and Treatment OptionsClinical Infectious Diseases, 2008
- The Epidemiological Profile of Infections with Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter SpeciesClinical Infectious Diseases, 2006
- Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclinesJournal of Antimicrobial Chemotherapy, 2006
- Clinical impact and pathogenicity of AcinetobacterClinical Microbiology and Infection, 2005
- Clinical Pharmacokinetics of Doxycycline and MinocyclineClinical Pharmacokinetics, 1988
- In Vitro and In Vivo Activities of Minocycline and Other Antibiotics Against Acinetobacter ( Herellea-Mima )Antimicrobial Agents and Chemotherapy, 1976